Oppenheimer Upgrades Inovio Pharmaceuticals to Outperform, Announces $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh has upgraded Inovio Pharmaceuticals (NASDAQ:INO) from Perform to Outperform and set a price target of $4. This upgrade reflects a positive outlook on the company's stock by the analyst.
January 25, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inovio Pharmaceuticals has been upgraded by Oppenheimer from Perform to Outperform with a new price target of $4, indicating a bullish stance on the stock.
Upgrades by analysts, especially from neutral to outperform, can lead to increased investor confidence and a potential short-term rise in the stock price. The new price target of $4 suggests a significant upside from the current trading level, which may attract investors looking for growth opportunities.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100